Pharma: Other News To Note

2010-03-28 23:01:00 • Ablynx NV, of Ghent, Belgium, modernized ALX-0171 in to preclinical growth for respiratory synctial pathogen (RSV). ALX-0171 is an inhaled Nanobody claimant which holds to RSV as well as neutralizes a virus.

• Actelion Ltd., of Allschwil, Switzerland, lengthened a partnership with Singapore-based Invida Pharmaceutical Holdings Pte. Ltd.for one after another Asian commercialization of Tracleer (bosentan) for pulmonary arterial hypertension. The stipulate runs by 2015 as well as covers Thailand, Malaysia, Philippines, Vietnam as well as Hong Kong. Terms were not disclosed.

• Adventrx Pharmaceuticals Inc., of San Diego, will encounter with a FDA during a final week of Apr to plead a brand brand brand brand new drug focus for ANX-530 (vinorelbine injectable emulsion), which perceived a refuse-to-file minute progressing this month due to production deficiencies. ANX-530 is an mixture of a chemotherapy drug vinorelbine, as well as Adventrx is looking capitulation for non-small-cell lung cancer. (See BioWorld Today, Mar 2, 2010.)

• ARCA Biopharma Inc., of Broomfield, Colo., saw a shares spike 210 percent upon headlines which it was postulated a U.S. obvious for a heart disaster drug, Gencaro (bucindolol). Patent No. 7,678,842, patrician “Methods for Treatment with Bucindolol Based upon Genetic Targeting,” provides insurance in to 2025. ARCA has submitted a revised clinical custom for examination underneath a special custom comment routine for a hearing involving about 3,200 patients with ongoing heart disaster and, upon obtaining enough funding, pronounced it could proceed a investigate about a year later. Gencaro formerly perceived fast-track nomination for a rebate of cardiovascular mankind as well as cardiovascular hospitalizations in a genotype-defined heart disaster population. Shares of ARCA (NASDAQ:ABIO) gained $5.57 to tighten Friday during $8.22.

• Cipher Pharmaceuticals Inc., of Mississauga, Ontario, pronounced a brand brand brand brand new drug acquiescence to Health Canada for CIP-Tramadol ER, an extended-release plan of tramadol, has been supposed for review. The association pronounced it expects a examination to be finished by early 2011.

• The Medicines Co., of Parsippany, N.J., pronounced it filed a censure opposite a U.S. Patent as well as Trademark Office, a FDA as well as Health as well as Human Services looking to set in reserve a PTO’s rejection final week of a firm’s Feb. 14, 2001, Hatch-Waxman focus to magnify a principal U.S. obvious covering Angiomax (bivalirudin). The complaint, filed in a U.S. District Court for a Eastern District of Virginia, is compared to a box motionless upon Mar 16, where a same justice set in reserve a PTO’s before rejection of The Medicine Co.’s focus as well as sent a make a difference behind to a PTO for reconsideration. The PTO released a brand brand brand brand new rejection Mar 19. The box is a consequence of The Medicines Co. presumption a 60-day duration for filing a obvious tenure prolongation proposed upon Dec. 18, 2000, a Monday, rsther than than Friday, Dec. 15, 2000, when it perceived an afterhours capitulation for Angiomax. Leerink Swann researcher Joseph Schwartz pronounced Friday he one after another to hold which a association would not overcome in a track of suing a government. (See BioWorld Today, Mar 23, 2010.)

• Vantia Therapeutics Ltd., of Southampton, UK, reported which a dysmenorrhea claimant VA111913 has been shown to revoke extreme contraction of well-spoken muscle, such as which found in a uterus wall. The drug is written to aim vasopressin receptors for determining contractions compared with duration pain. VA111913 is in Phase II testing, with formula approaching in a second half of this year. Data were presented during a American Chemical Society assembly in San Francisco.

• Vivus Inc., of Mountain View, Calif., pronounced a FDA reliable which a Endocrinologic as well as Metabolic Drugs Advisory Committee is tentatively scheduled to examination a firm’s brand brand brand brand new drug focus for Qnexa for a diagnosis of plumpness upon Jul 15. The association noted, however, which a group has nonetheless to strictly make known a assembly in a Federal Register. Vivus upon Dec. 28, 2009, submitted a NDA, which was supposed for examination by a FDA upon Mar 1. Leerink Swann researcher Steve Yoo expected which a same cabinet expected would examination San Diego-based Arena Pharmaceutical Inc.’s plumpness drug lorcaserin during a same meeting. Arena submitted a NDA for lorcaserin upon Dec. 22, 2009. (See BioWorld Today, Jan. 8, 2010.)